LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic
LabGenius' CTO, Leonard Wossnig, discusses the intersection of synthetic biology, high-throughput assays, and machine learning in the quest for cancer drugs with Harry Glorikian
BBC News covers LabGenius and how it harnesses AI in the search for new medicines
LabGenius' CEO, James Field, discusses ML-enabled drug discovery with Patrick Short on the Genetics Podcast
PwC | The Life Sciences Future50
The Bio Report | Leveraging Generative AI to Design Therapeutic Antibodies
CogX Presentation | Breaking Through the 'Cognition Barrier' to Discover Novel Therapeutics
LabGenius’ Research Collaboration with Sanofi Yields Positive Results
SynBioBeta | Machine Learning Enhances Antibody Discovery: A Glimpse into LabGenius and Sanofi's Collaborative Endeavour
TechCrunch | Questions Every VC Needs to Ask About Every AI Startup’s Tech Stack
Single-domain Antibody Conference, Paris | Poster Presentation
WIRED Feature | AI is Building Highly Effective Antibodies That Humans Can’t Even Imagine
Immuno-oncology Summit | Poster Presentation
Immuno-oncology Summit | Speaker Presentation
Blog post | LabGenius' CTO, Leonard Wossnig, introduces the 5 'V's of drug discovery data in a recent blog post
LabGenius hosts the UK's Minister for AI at their 4,000 sq. ft state-of-the-art protein engineering facility in central London
LabGenius' CEO, James Field, discusses ML-enabled drug discovery as a recent guest on the Business of Biotech podcast
LabGenius featured in the inaugural edition of the Decoding Bio Snapshot
LabGenius' CEO & founder appeared live on Bloomberg News to talk about the drug discovery revolution that's taking place at the interface of biology and technology
Catch the latest results from LabGenius' ML-driven T-cell engager optimisation capability in Labiotech.eu
